CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
Noeul Kang, Ki Hwan Kim, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, O Jung Kwon, Myung-Ju Ahn, Jeonghee Cho, Ho Yun Lee, Sang-Won Um
Cancer Research and Treatment. 2022;54(3):817-826.   Published online 2021 November 9    DOI: https://doi.org/10.4143/crt.2021.822

Excel Download

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer
Cancer Research and Treatment. 2022;54(3):817-826   Crossref logo
Link1 Link2 Link3

CLINICAL ANALYSIS OF AFATINIB IN EGFR-TYROSINE KINASE INHIBITOR NAÏVE PATIENTS WITH NON-SMALL CELL LUNG CANCER HABORING EGFR MUTATIONS
Respirology. 2017;22:114-114   Crossref logo
Link1 Link2

Comment on: Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC
Lung Cancer. 2019;127:167   Crossref logo
Link1 Link2

Plasma MIP-1β levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib
Lung Cancer. 2005;50(3):393-399   Crossref logo
Link1 Link2

76: Patterns of extra-cranial disease progression in epidermal growth factor receptor (EGFR) mutant metastatic non-small cell lung cancer (NSCLC) patients on a tyrosine kinase inhibitor (TKI)
Lung Cancer. 2015;87:S30   Crossref logo
Link1 Link2

Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients
Lung Cancer. 2018;123:60-69   Crossref logo
Link1 Link2

Readministration of EGFR Tyrosine Kinase Inhibitor in Non-small Cell Lung Cancer Patients after Initial Failure, What Affects its Efficacy?
Scientific Reports. 2014;4(1):   Crossref logo
Link1 Link2 Link3

INCIDENCE OF HEPATITIS B REACTIVATION DURING EGFR TYROSINE KINASE INHIBITORS TREATMENT IN NON-SMALL-CELL LUNG CANCER PATIENTS
Respirology. 2018;23:291-291   Crossref logo
Link1 Link2

RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation
Lung Cancer. 2015;90(3):477-483   Crossref logo
Link1 Link2

EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Lung Cancer. 2016;96:87-92   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.